Pralatrexate (Pralatrexate) is the first drug to treat PTCL as a new anticancer drug. It has been reported that praltrexacin is a novel targeted folic acid formulation, which can preferentially cluster in cancer cells and can be used alone to treat recurrent and refractory PTCL. It can not only completely inhibit dihydrofolate reductase (DHFR), but also competitively inhibit the glutenamine action of phylloyl polyglutamyl synthetase. Blocking the synthesis of thymine and other biomolecules dependent on single carbon transfer, by interfering with DNA synthesis, promote the death of tumor cells, to achieve therapeutic effects. At present, foreign clinical experts have begun to use pratoxacin in the treatment of PTCL, but the domestic application is still in the clinical trial stage.

 

Target: DHFR

 

Melting Point: 215 °C(dec.)

 

Bioactivity: Pralatrexate is an antifolate with a similar structure to folic acid and acts on some cell lines with IC50 below 300 nM. Pralatrexate can induce apoptosis of tumor cells.

 

Solubility: ≥23.85 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH. 

 

Attribute
[Chem Name]	10-Propargyl-10-deazaaminopterin
[Synonym]	Pralatrexate
[CAS No.]	146464-95-1
[MDL No.]	MFCD00920897
[Formula]	C23H23N7O5
[Molecular]	477.47
[Form]	White to light yellow powder to crystal
[Risk Codes]	GHS07, GHS08
[Storage]	2-8 °C

Goods Tag